Modulation of estrogen receptor transactivation and estrogen-induced gene expression by ormeloxifene-A triphenylethylene derivative

Steroids

Volumn 71, Issue 11-12, 2006, Pages 993-1000

  Blesson, Chellakkan S ^a   Awasthi, Smita ^a   Kharkwal, Geetika ^a   Daverey, Amita ^a   Dwivedi, Anila ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Estrogen receptor; Ormeloxifene; Transactivation; Uterus

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; CENTCHROMAN; ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL STRAIN COS1; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; MODULATION; NONHUMAN; ORGAN WEIGHT; RAT; TRANSACTIVATION; TRANSCRIPTION INITIATION; UTERUS;

ANIMALS; BENZOPYRANS; CERCOPITHECUS AETHIOPS; COS CELLS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MOLECULAR STRUCTURE; OVARIECTOMY; RATS; RECEPTORS, PROGESTERONE; RESPONSE ELEMENTS; STILBENES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTIONAL ACTIVATION; UTERUS;

EID: 33749983404     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2006.08.001     Document Type: Article

References (33)

1. Kuiper G.G.J.M., Carlsson K., Grandian K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J.A. Comparision of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 (1997) 863-870
2. Mitlak B.H., and Cohen F.J. Selective estrogen receptor modulators: a new look ahead. Drugs 57 (1998) 653-663
3. Macgregor J.I., and Jordan V.C. Basic guide to mechanisms of antiestrogen action. Pharmacol Rev 50 (1998) 151-196
4. Kamboj V.P., Ray S., and Dhawan B.N. Centchroman. Drug Today 28 (1992) 227-232
5. Dhar J.D., Dwivedi A., Srivastava A., and Setty B.S. Structure activity relationship of some 2,3-diaryl-2H-1-benzopyrans to their anti-implantation, estrogenic and antiestrogenic activities in rat. Contraception 49 (1994) 609-615
6. Martel C., Picard S., Richard V., Belanger A., Labrie C., and Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomizd rats. J Steroid Biochem Mol Biol 74 (2000) 45-56
7. Willson T.M., Norris J.D., Wagner B.L., Asplin I., and Baer P. Dissection of the molecular mechanism of action of GW3638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinolgy 138 (1997) 3901-3911
8. Qu Q., Zheng H., Dhallund J., Laive A., Cockroft N., Peng Z., Kockinen M., Heminki K., Kangas L., Vaananen K., and Harkonen P. Selective estrogenic effect of a novel triphenylethylene compound, FC 1271a, on bone, cholesterol level and reproductive tissues in intact and ovariectomized rats. Endocrinology 141 (2000) 809-820
9. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. JAMA 282 (1999) 637-645
10. Dwivedi A., Bansode F.W., Setty B.S., and Dhar J.D. Endometrial steroid receptors during decidualization in rhesus monkey (Macaca mulatta); their modulation by antiestrogen CDRI-85/287. Hum Reprod 14 (1999) 1090-1095
11. Kamboj V.P., Setty B.S., Chandra H., Roy S.K., and Kar A.B. Biological profile of centchroman-a new post-coital contraceptive. Ind J Exp Biol 15 (1977) 1144-1150
12. Singh M.M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone related clinical disorders. Med Res Rev 21 (2001) 302-347
13. Dwivedi A., Basu R., Chowdhury S.R., and Goyal N. Modulation of estrogen action during pre-implantation period and in immature estradiol-primed rat uterus by anti implantation agent ormeloxifene. Contraception 71 (2005) 458-464
14. Arshad M., Sengupta S., Sharma S., Ghosh R., Sawlani V., and Singh M.M. In vitro anti-resorptive activity and prevention of ovariectomy induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator. J Steroid Biochem Mol Biol 91 (2004) 67-78
15. Srivastava S., Sharma R., and Balapure A.K. Morphological and biochemical basis of centchroman as a novel antineoplastic agent in MCF-7 human breast cancer cells. Ind J Pharmacol 36 (2004) 238-243
16. Tripathi S., Dwivedi I., Dhar J.D., Dwivedi A., and Ray S. Evaluation of pyrrolidinoethoxy moiety as an antiestrogenic substitute in non-steroidal antiestrogens: fertility regulation. Bioorg Med Chem Lett 7 (1997) 2131-2136
17. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., Van der Saag P.T., Van der Burg B., and Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 (1998) 4252-4263
18. Darwish H., Krisinger J., Furlow J.D., Smith C., Murdoch F.E., and DeLuca H.F. An estrogen responsive element mediates the transcriptional regulation of calbindin D-9K in rat uterus. J Biol Chem 266 (1991) 551-558
19. Kumar V., and Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156
20. Bradford M.N. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
21. Navarro D., Leon L., Chirino R., Fernandez L., Pestano J., and Diaz-chico B.N. The two native estrogen receptor forms of 8S and 4S present in cytosol from human uterine tissue display opposite reactivities with the antiestrogen Tam Aziridine and the estrogen responsive element. J Steroid Biochem Mol Biol 64 (1998) 49-58
22. Valentine J.E., Kalkhoven E., White R., Hoare S., and Parker M.G. Mutation in the estrogen binding domain discriminate between hormone dependent transactivation and transrepression. J Biol Chem 275 (2000) 25322-25329
23. Fan M., Long X., Bailey J.A., Reed C.A., Osborne E., Gize E.A., Kirk E.A., Bigsby R.M., and Nephew K.P. The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16 (2002) 315-330
24. Nudel U., Zakut R., Shani M., Neuman S., Levy Z., and Yaffe D. The nucleotide sequence of the rat cytoplasmic β-actin gene. Nucl Acids Res 11 (1983) 1579-1771
25. 50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
26. Craig D. The Cheng-Prusoff relationship; something lost in the translation. Trends Pharmacol Sci 14 (1993) 89-91
27. Katzenellenbogen B.S., and Korasch K.S. Editorial: a new actor in the estrogen receptor drama, enter ERβ. Endocrinology 138 (1997) 861-862
28. Rivera-Gonzalez R., Peterssen D.N., Tkalcevic G., Thompson D.D., and Brown T.A. Estrogen-inducd genes in the uterus of ovariectomised rats and their regulation by raloxifene and tamoxifen. J Steroid Biochem Mol Biol 64 (1998) 13-24
29. Chen D., Xu X., Zhu Li J., Angersto M., Li Q., Bagchi M.K., and Bagchi I.C. Cloning and uterus/oviduct specific expression of a novel estrogen-regulated gene ERG1. J Biol Chem 274 (1999) 32215-32224
30. Alexendersen P., Riis B.J., Stakkestad P.D., Delmas P.D., and Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocr Metab 86 (2001) 755-760
31. Durani S., and Anand N. A possible basis for structure function relationship of estrogens. Int J Quant Chem 20 (1981) 71-76
32. Klinge C.M., Trash A.M., Bambara R.A., and Hilf R. Dissociation of 4-hydroxyTam but not estradiol or Tam aziridine from the estrogen receptor when that receptor binds estrogen response element DNA. J Steroid Biochem Mol Biol 57 (1996) 51-66
33. Komm B.S., Kharode Y.P., Bodine P.V.N., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008